Article

ASCO 2012 ... the latest in cancer research

Author(s):

Elizabeth Whittington

We are all gearing up for the largest oncology meeting of the year, the annual meeting of the American Society of Clinical Oncology. What's great about this meeting is we hear both the up-and-coming, early phase studies, but also the late-phase studies. These studies could truly change clinical practice for patients.If you have a minute, take a look at the ASCO schedule and let us know if there is anything that you want to know more about!

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Related Content
Image of woman.
June 18th 2025

When a “Thinking of You” Card Isn’t the Right Support for a Patient

Sue McCarthy
Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Image of lung.
June 18th 2025

Recent SCLC Data May Impact How Patients Are Treated Day-to-Day

Ryan Scott
Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of hands.
June 18th 2025

The Person Behind Their Diagnosis: Understanding the Patient

Ryan Scott
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer: © stock.adobe.com.
June 18th 2025

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

Spencer Feldman
Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.